)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Nektar Therapeutics (NKTR) investor relations material
Nektar Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary6 Nov, 2025
Executive summary
Advancing rezpegaldesleukin (REZPEG) into phase 3 for atopic dermatitis, with phase 2b data in alopecia areata expected December 2025; Fast Track designations granted for both indications.
Pipeline includes ongoing studies in type 1 diabetes, NKTR-255 in oncology, and preclinical programs NKTR-0165 and NKTR-0166.
REZPEG recognized in Nobel Prize background documents for its role in T reg science and clinical efficacy in autoimmune disease.
Sale of manufacturing facility completed in December 2024, shifting supply to Gannet BioChem and resulting in equity method investment.
Chief Medical Officer Mary Tagliaferri rejoined, strengthening clinical leadership.
Financial highlights
Ended Q3 2025 with $270.2 million in cash and investments, no debt.
Q3 2025 revenue was $11.8M, down 51% year-over-year, due to the sale of the Huntsville facility; nine-month revenue was $33.4M.
Net loss for Q3 2025 was $35.5M ($1.87/share); nine-month net loss was $128.0M ($8.14/share).
Raised $107.2M from a secondary public offering, $34.3M from ATM facility in Q3, and $38.3M in October.
No product sales or cost of goods sold recognized in 2025 post-facility sale.
Outlook and guidance
Cash and investments expected to support operations into Q2 2027.
Anticipates end-of-phase 2 FDA meeting for REZPEG in atopic dermatitis by year-end; phase 3 program planned for next year.
Research and development expenses expected to increase slightly in 2025 as phase 3 activities commence.
Topline data from phase 2b RESOLVE-AA study in alopecia areata expected in December 2025.
Plans to advance TNF-R2 agonist antibody program into the clinic in 2026.
How does REZPEG's asthma co-morbidity data impact its market position?
What milestones extend cash runway beyond Q2 2027?
How does R&D spend shift reflect pipeline priorities?
REZPEG's AD/asthma data: market impact?
AA Phase III: partnership or solo development?
Next antibody program: specific target/indication?
REZPEG's asthma comorbidity data impact on AD
REZPEG AA efficacy vs. JAKs, considering safety
Nektar 0165 bispecifics: next steps and timeline?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Nektar Therapeutics earnings date
Jefferies London Healthcare Conference 202520 Nov, 2025
Next Nektar Therapeutics earnings date
Jefferies London Healthcare Conference 202520 Nov, 2025
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Nektar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of novel therapies. These therapies aim to selectively modulate the immune system to treat autoimmune disorders, chronic inflammatory conditions, and cancer.The company uses proprietary PEGylation and advanced polymer conjugate technologies to modify the chemical structure of substances, facilitating the development of new drug candidates. It is headquartered in San Francisco, California, and its shares are listed on the NASDAQ under the ticker symbol NKTR.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage